Abstract
Background Flavivirus infections pose a significant global health burden underscoring the need for the development of safe and efficient vaccination strategies. Available flavivirus vaccines are from time to time concomitantly delivered to individuals in need. Co-administration of different vaccines saves time and visits to health care units and vaccine clinics. It serves to provide protection against multiple pathogens in a shorter time-span, both for individuals living in, or travelling to, endemic areas. However, safety and immunogenicity-related responses have not been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we performed an open label, non-randomized clinical trial studying the safety and immunogenicity following concomitant delivery of the Yellow fever virus (YFV) vaccine with Tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines.
Methods and findings Following screening, healthy study subjects were enrolled into different cohorts receiving either TBEV and YFV vaccines, JEV and YFV vaccines, or in control groups receiving only the TBEV, JEV, or YFV vaccine. Concomitant delivery was given in the same or different upper arms for comparison in the co-vaccination cohorts. Adverse effects were recorded throughout the study period and blood samples were taken before and at multiple time-points following vaccination to evaluate immunological responses to the vaccines. Adverse events were predominantly mild in the study groups. Four serious adverse events (SAE) were reported throughout the trial, none of them deemed related to vaccination. The development of neutralizing antibodies (nAbs) against TBEV, JEV, or YFV was not affected by the concomitant vaccination strategy. Concomitant vaccination in the same or different upper arms did not significantly affect safety or immunogenicity-related outcomes. Exploratory studies on immunological effects were additionally performed and included studies of lymphocyte activation, correlates associated with germinal center activation, and plasmablast expansion.
Conclusions Inactivated TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine without an increased risk of adverse events and without reduced development of nAbs to the respective viruses. The vaccines can be delivered in the same upper arm without negative outcome.
Trial registration Eudra CT 2017-002137-32
Why was this study done?
Flavivirus infections pose a significant global health burden, underscoring the need for the development of safe and efficient vaccination strategies
Co-administration of different flavivirus vaccines saves time and visits to health care units and vaccine clinics. It serves to provide protection against multiple pathogens in a shorter time-span, both for individuals living in or travelling to endemic areas
Safety and immunogenicity-related responses have not been appropriately evaluated upon co-administration of many vaccines including currently used flavivirus vaccines, such as Yellow fever virus (YFV), Tick-borne encephalitis virus (TBEV), and Japanese encephalitis virus (JE) virus vaccines
Because of this, we performed an open label, non-randomized clinical trial studying the safety and immunogenicity following co-administration of YFV vaccine with TBEV and JEV vaccines
What did the researchers find?
Adverse events, neutralizing antibodies (nAbs) and other related immunological parameters were not adversely affected by concomitant delivery of the vaccines
Concomitant vaccination in the same versus different upper arms of study participants did not significantly affect safety or immunogenicity outcomes
What do these findings mean?
Co-administration of YFV vaccine and TBEV or JEV vaccines is feasible without increased risk of adverse events or reduced development of nAbs against the respective viruses. Furthermore, the vaccines can safely be delivered in the same upper arm without negative outcome
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Eudra CT 2017-002137-32
Funding Statement
Yes. HGL, Swedish Research Council (2015-02499, 2020-01365), www.vr.se. HGL, Swedish Foundation for Strategic Research (SB12-0003), www.strategiska.se. HGL and KB, Region Stockholm (CIMED 2020-2022), www.regionstockholm.se. HGL, Karolinska Institutet (HGL), www.ki.se. HGL, KID PhD student funding grant from Karolinska Institutet for JTS, www.ki.se The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Swedish Ethical Review Authority
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared senior author (alphabetic order)
Funding This work was supported by the Swedish Research Council (2015-02499, 2020-01365; HGL), the Swedish Foundation for Strategic Research (SB12-0003; HGL), Region Stockholm (CIMED 2020-2022; HGL and KB), Karolinska Institutet (HGL), and a KID PhD student funding grant from Karolinska Institutet (for JTS; HGL).
URLs to sponsors’ websites https://ki.se/en/medh/hans-gustaf-ljunggren-group-immune-responses-to-human-virus-infections-and-cancer
Competing interest The authors declare no competing interest
Data Availability
All relevant data are within the manuscript and its Supporting Information files.